pulmonary fibrosis
Information
- Disease name
- pulmonary fibrosis
- Disease ID
- DOID:3770
- Description
- "An interstitial lung disease that is characterized by destruction, scarring, and thickening of the interstitial lung tissues and progressive pulmonary function loss in a restrictive pattern, has_symptom progressive shortness of breath, fatigue, and chronic cough, possibly has_material_basis_in exposure to certain chemicals, autoimmune conditions, and radiation." [url:https\://www.sciencedirect.com/science/article/pii/S0954611106004331]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04136223 | Active, not recruiting | Rheumatoid Arthritis-Associated Interstitial Lung Disease: Characterization of Lung Disease Progression | March 1, 2021 | May 31, 2024 | |
| NCT04987528 | Active, not recruiting | Pulmonary Fibrosis During Severe COVID-19 Pneumonia | March 11, 2020 | December 31, 2025 | |
| NCT00258544 | Active, not recruiting | Microarray Analysis of Gene Expression in Idiopathic Pulmonary Fibrosis (IPF) | October 2001 | July 2030 | |
| NCT04964115 | Active, not recruiting | Post Acute Sequelae of COVID-19 | August 10, 2021 | May 2027 | |
| NCT05330312 | Active, not recruiting | N/A | Controlled Investigation to Evaluate Impact of dCBT on Psychological Symptom Burden in Adult Subjects With PF | April 17, 2022 | November 2023 |
| NCT04432545 | Available | Infusion of Allogeneic Mesenchymal Stem Cells in Patients With Diffuse Cutaneous Systemic Sclerosis With Refractory Pulmonary Involvement | |||
| NCT05356052 | Available | Expanded Access for Patients With Pulmonary Hypertension Associated With Pulmonary Fibrosis | |||
| NCT00005317 | Completed | Idiopathic Pulmonary Fibrosis--Pathogenesis and Staging - SCOR in Occupational and Immunological Lung Diseases | December 1986 | November 1996 | |
| NCT00016627 | Completed | Linkage Study in Familial Pulmonary Fibrosis | August 2000 | July 2005 | |
| NCT00052052 | Completed | Phase 2 | An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF) | September 2002 | September 2004 |
| NCT00063869 | Completed | Phase 2 | Study Evaluating the Safety and Efficacy of Etanercept in Patients With Idiopathic Pulmonary Fibrosis | March 2005 | |
| NCT00070590 | Completed | Phase 2/Phase 3 | Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With Scleroderma | July 2003 | September 2005 |
| NCT00080223 | Completed | Phase 2 | Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis | August 31, 2003 | April 30, 2015 |
| NCT00109681 | Completed | Phase 2 | Inhaled Iloprost in Adults With Abnormal Pulmonary Pressure and Associated With Idiopathic Pulmonary Fibrosis | April 2005 | October 2006 |
| NCT00131274 | Completed | Phase 2/Phase 3 | Gleevec Idiopathic Pulmonary Fibrosis (IPF) Study | April 2003 | August 2007 |
| NCT04987606 | Completed | Post COVID-19 Interstitial Lung Disease: A Study of Genetic and Environmental Interactions | July 1, 2021 | April 1, 2024 | |
| NCT00001596 | Completed | Phase 2 | Oral Pirfenidone for the Pulmonary Fibrosis of Hermansky-Pudlak Syndrome | September 2005 | May 9, 2016 |
| NCT00001618 | Completed | Segmental Bronchoalveolar Lavage | November 18, 1996 | August 31, 2018 | |
| NCT00001876 | Completed | Lung Disease Associated With Rheumatoid Arthritis | April 5, 1999 | December 11, 2007 | |
| NCT00001884 | Completed | Specimen Collection for Individuals With Lung Disease Associated With Rheumatoid Arthritis | March 21, 1999 | December 28, 2007 | |
| NCT00001885 | Completed | Identification of Genes Associated With Lung Disease in Patients With Rheumatoid Arthritis | March 21, 1999 | December 28, 2007 | |
| NCT00004563 | Completed | Phase 3 | Scleroderma Lung Disease | August 1999 | May 2013 |
| NCT00352482 | Completed | Phase 2 | Sildenafil to Increase Exercise Capacity in Individuals With Idiopathic Pulmonary Fibrosis and Pulmonary Hypertension | November 2004 | July 2007 |
| NCT00366509 | Completed | Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases | September 18, 2006 | October 27, 2016 | |
| NCT00455767 | Completed | Phase 2 | Safety and Efficacy Study of Depelestat in Acute Respiratory Distress Syndrome (ARDS) Patients | July 2006 | September 2007 |
| NCT00457301 | Completed | Using Health-related Quality of Life (HRQL) in Routine Clinical Care | July 2005 | May 2008 | |
| NCT00504621 | Completed | The Influence of Personality on Pulmonary Fibrosis and Sarcoidosis | August 2007 | January 2009 | |
| NCT00514683 | Completed | Phase 2 | Safety And Efficacy of BIBF 1120 in Idiopathic Pulmonary Fibrosis | August 2007 | |
| NCT00517933 | Completed | Phase 3 | Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis | August 2007 | October 2009 |
| NCT00563212 | Completed | Phase 1 | A Pilot Study of Aerosol Interferon-gamma for Treatment of Idiopathic Pulmonary Fibrosis | January 2007 | December 1, 2018 |
| NCT00611182 | Completed | Dyspnea in Patients With Pulmonary Fibrosis | January 2008 | March 2010 | |
| NCT00639496 | Completed | Phase 3 | Study of the Effects of High-dose N-acetylcysteine (NAC) in Idiopathic Pulmonary Fibrosis (IPF) | March 2000 | July 2003 |
| NCT00650091 | Completed | Phase 3 | Evaluating the Effectiveness of Prednisone, Azathioprine, and N-acetylcysteine in Patients With IPF | October 2009 | January 2014 |
| NCT00786201 | Completed | Phase 2 | A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary Fibrosis (IPF) | December 2008 | January 2012 |
| NCT00911794 | Completed | N/A | Written Disclosure Therapy for Anxiety and Stress in Patients With Chronic Lung Disease | January 2007 | March 2009 |
| NCT01121367 | Completed | Study on Phenotypic Characterization of Combined Pulmonary Fibrosis and Emphysema | May 2010 | June 2011 | |
| NCT01170065 | Completed | Phase 2 | Roll Over Study From 1199.30 BIBF 1120 in Idiopathic Pulmonary Fibrosis (IPF) | June 25, 2010 | September 26, 2016 |
| NCT01271842 | Completed | Long-term Outcome and Lung Capacity in Survivors of ARDS Due to Influenza A (H1N1) v2009 The RESPIFLU Study | October 2010 | ||
| NCT01335464 | Completed | Phase 3 | Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients | April 2011 | October 2013 |
| NCT01335477 | Completed | Phase 3 | Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients II | May 2011 | October 2013 |
| NCT01417156 | Completed | Phase 2 | Safety and PK Study of BIBF 1120 in Japanese Patients With IPF: Follow up Study From 1199.31(NCT01136174) | September 2011 | October 2015 |
| NCT01417520 | Completed | Clinical and Pathophysiological Investigations Into Erdheim Chester Disease | August 1, 2011 | July 24, 2019 | |
| NCT01442779 | Completed | Phase 2 | Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary Fibrosis | September 2000 | May 2007 |
| NCT01501578 | Completed | Pulmonary Fibrosis and Telomerase Mutation Study | December 2011 | December 2015 | |
| NCT01615484 | Completed | N/A | Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability | September 2013 | January 2017 |
| NCT01653730 | Completed | N/A | Comparative Study of 3 Portable Oxygen Concentrators During a 6-minute Walk Test in Patients With Chronic Lung Disease | February 2010 | August 2010 |
| NCT01687946 | Completed | Explorative Study on the Molecular Pathology of Lung Fibrosis by Combination of Clinical Assessment and System Biology | June 2010 | August 2014 | |
| NCT01825538 | Completed | Assessment of Pulmonary Specialty Physicians' Approach to Advanced Care Planning in Patients With Chronic Pulmonary Diseases | February 2013 | June 2014 | |
| NCT01916577 | Completed | Phase 1 | Autologous CD117+ Progenitor Cell Mobilization for Lung Transplantation | August 2013 | December 2017 |
| NCT01961362 | Completed | Supplemental Oxygen in Pulmonary Fibrosis | October 2013 | December 2016 | |
| NCT02055222 | Completed | Clinical Outcomes and Molecular Phenotypes in Smokers With Parenchymal Lung Disease | October 14, 2014 | August 23, 2018 | |
| NCT02510937 | Completed | Phase 1 | Safety and PK Study of CC-90001 in Subjects With Pulmonary Fibrosis | August 5, 2015 | February 6, 2017 |
| NCT02594059 | Completed | N/A | Assessment of Peripheral Endothelial Function in Idiopathic Pulmonary Fibrosis | December 19, 2012 | July 15, 2020 |
| NCT02668029 | Completed | Phase 2 | Effect of Ambulatory Oxygen on the Walking Test in Patients With Pulmonary Fibrosis | April 2012 | April 2013 |
| NCT02771184 | Completed | N/A | Computerized Lung Sound Analysis | April 2016 | March 2018 |
| NCT03242759 | Completed | Non-Interventional Study (NIS) Collecting Experiences For IPF in Taiwan | August 17, 2017 | February 18, 2020 | |
| NCT03385668 | Completed | Phase 2 | Pilot Study of Pirfenidone in Pulmonary Fibrosis With Anti-myeloperoxydase Antibodies | January 31, 2018 | July 24, 2020 |
| NCT03462524 | Completed | Neoadjuvant Therapy for Esophageal Cancer and Cardiopulmonary Physiology | January 1, 2010 | January 1, 2018 | |
| NCT03542318 | Completed | Effects of Pulmonary Rehabilitation on Functional and Health Status Measures in Pulmonary Fibrosis | March 1, 2014 | January 31, 2016 | |
| NCT03567785 | Completed | Supporting Adherence to Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis | July 17, 2018 | February 11, 2021 | |
| NCT03727451 | Completed | Phase 2 | A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis or Sarcoidosis | January 30, 2019 | June 15, 2022 |
| NCT04308681 | Completed | Phase 2 | A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis | July 29, 2020 | September 22, 2023 |
| NCT04488562 | Completed | Home Monitoring and Evaluation After Admission for COVID-19 in the Netherlands | March 19, 2020 | February 26, 2022 | |
| NCT04619680 | Completed | Phase 4 | The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19 | November 18, 2020 | March 1, 2024 |
| NCT04979884 | Completed | Phase 3 | Safety and Effectiveness of Cyclosporin in the Management of COVID19 ARDS Patients in Alexandria University Hospital | January 3, 2022 | December 9, 2022 |
| NCT00000596 | Completed | Phase 2 | Diffuse Fibrotic Lung Disease | June 1978 | January 1983 |
| NCT05670587 | Completed | N/A | A Study in People With Pulmonary Fibrosis to Monitor Cough With a Wearable Device | January 16, 2023 | March 7, 2024 |
| NCT05711290 | Completed | N/A | Oxygen Nanobubble Drink Impact on Exercise in Pulmonary Fibrosis | March 21, 2023 | August 9, 2023 |
| NCT05981885 | Completed | 68Ga-FAPI PET/CT to Detect Ongoing Fibroblast Activity in Post-acute COVID-19 | June 9, 2022 | May 17, 2024 | |
| NCT06160440 | Completed | Phase 1 | The Safety, Tolerability, and Pharmacokinetic Study of SC1011 in Healthy Subjects. | June 3, 2021 | February 23, 2022 |
| NCT06179342 | Completed | Multiple Breath Washout as a Method for Diagnosing Lung Diseases | June 21, 2021 | March 1, 2024 | |
| NCT06304623 | Completed | Phase 1 | SVF for Treating Pulmonary Fibrosis Post COVID-19 | May 5, 2020 | March 1, 2024 |
| NCT06423560 | Completed | Pulmonary Fibrosis After Severe COVID-19 Pneumonia | March 1, 2020 | May 16, 2024 | |
| NCT06457269 | Completed | N/A | Evaluating the Potential of Large Language Models for Respiratory Disease Consultations | October 1, 2023 | April 4, 2024 |
| NCT04930289 | Enrolling by invitation | Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs | October 15, 2021 | December 30, 2025 | |
| NCT06327360 | Enrolling by invitation | Illness Expectations in Pulmonary Fibrosis | October 10, 2023 | October 1, 2025 | |
| NCT06399094 | Not yet recruiting | Frequency-time Analysis of Pathological Lung Sounds: Detection and Quantification of Pathological Sounds in Patients With Cystic Fibrosis, Pulmonary Fibrosis or COPD (Chronic Obstructive Pulmonary Disease) | June 1, 2024 | January 1, 2025 | |
| NCT06122233 | Not yet recruiting | N/A | REBUILD-SM Study for People With Interstitial Lung Disease (ILD) | May 2024 | August 2027 |
| NCT06124859 | Not yet recruiting | N/A | Exercise Tolerance and Lower-limb Muscle Power in Patients With Chronic Respiratory Disease | November 2023 | December 2024 |
| NCT05174741 | Not yet recruiting | N/A | Pulmonary Rehabilitation in Non-chronic Obstructive Pulmonary Disease Patients. | April 2023 | February 2024 |
| NCT05719038 | Not yet recruiting | Diagnostic and Prognostic Model of Pulmonary Fibrosis After COVID-19 Pneumonia and Mechanism Study | January 30, 2023 | December 30, 2024 | |
| NCT05899556 | Not yet recruiting | Pinpointing the Factors Affecting Clinical Study Experiences of Pulmonary Fibrosis Patients | July 2024 | July 2026 | |
| NCT06162884 | Not yet recruiting | Single Time Point Prediction as Earlier Diagnosis of Progressive Pulmonary Fibrosis | December 22, 2023 | December 31, 2027 | |
| NCT06251687 | Not yet recruiting | N/A | Application of Transbronchial Cryobiopsy in the Diagnosis of Progressive Pulmonary Fibrosis | February 1, 2024 | December 31, 2026 |
| NCT06275295 | Not yet recruiting | A Retrospective Study of Transbronchial Cryobiopsy in the Diagnosis of Progressive Pulmonary Fibrosis | March 20, 2024 | December 31, 2024 | |
| NCT05771740 | Not yet recruiting | Pulmonary Fibrosis Lung Sounds Study | March 2023 | December 2023 | |
| NCT02748798 | Recruiting | Early Phase 1 | Developing Optimal Parameters for Hyperpolarized Noble Gas and Inert Fluorinated Gas MRI of Lung Disorders | November 10, 2020 | December 22, 2023 |
| NCT03455686 | Recruiting | N/A | Exploring the Utility of Hyperpolarized 129Xe MRI in Healthy Volunteers and Patients With Lung Disease | April 19, 2018 | December 2024 |
| NCT04482595 | Recruiting | Phase 2 | BIO 300 Oral Suspension in Previously Hospitalized Long COVID Patients | November 11, 2020 | April 30, 2025 |
| NCT00258570 | Recruiting | Genetic Polymorphisms in Idiopathic Pulmonary Fibrosis (IPF) | January 2003 | July 2035 | |
| NCT06189820 | Recruiting | Phase 2 | Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases | March 9, 2023 | March 9, 2027 |
| NCT04564183 | Recruiting | Advancing Prevention of Pulmonary Fibrosis | January 22, 2021 | August 1, 2026 | |
| NCT05859763 | Recruiting | N/A | 99mTc-HFAPI SPECT/CT in Pulmonary Fibrosis | December 12, 2021 | July 1, 2024 |
| NCT04638517 | Recruiting | Phase 2 | The TELO-SCOPE Study: Attenuating Telomere Attrition With Danazol. Is There Scope to Dramatically Improve Health Outcomes for Adults and Children With Pulmonary Fibrosis | September 7, 2021 | June 2025 |
| NCT04680832 | Recruiting | N/A | Exhaled Breath Analysis Using eNose Technology as a Biomarker for Diagnosis and Disease Progression in Fibrotic ILD | November 1, 2020 | December 31, 2026 |
| NCT00515567 | Recruiting | Explanted Lung Tissues With Pulmonary Fibrosis | February 2006 | December 2024 | |
| NCT04767074 | Recruiting | N/A | A Non-pharmacological Cough Control Therapy | September 1, 2020 | December 2024 |
| NCT05635032 | Recruiting | Fibrosing ILD Biomarkers That Rule Acceleration | March 1, 2021 | March 31, 2026 | |
| NCT01917877 | Recruiting | Phase 2 | Efficiency Study for Acute Radiation-induced and Chemotherapy-induced Pulmonary Fibrosis With Bevasizumab | August 1, 2013 | December 30, 2025 |
| NCT04864990 | Recruiting | Dyspnea and Idiopathic Pulmonary Fibrosis | October 22, 2021 | October 2025 | |
| NCT03535545 | Recruiting | Phase 1 | Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis Patients | August 1, 2018 | June 30, 2026 |
| NCT04948203 | Recruiting | Phase 2/Phase 3 | Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis | July 9, 2021 | June 2024 |
| NCT05392881 | Recruiting | Interstitial Lung Disease Research Unit Biobank | August 9, 2021 | March 1, 2032 | |
| NCT05890573 | Recruiting | N/A | Efficacy of Bailing Capsule on Pulmonary Fibrosis After COVID-19 | April 16, 2024 | December 31, 2024 |
| NCT05387239 | Recruiting | Phase 2 | Safety and Effectiveness of VL-PX10 + VL-P22 Treatment on Pulmonary Fibrosis Secondary to Covid-19 | November 30, 2022 | December 2024 |
| NCT02852928 | Recruiting | European Management Platform for Childhood Interstitial Lung Diseases - chILD-EU Register and Biobank | December 2013 | December 2029 | |
| NCT00084305 | Recruiting | Analysis of Specimens From Individuals With Pulmonary Fibrosis | June 9, 2004 | ||
| NCT05382572 | Recruiting | Pulmonary Fibrosis Foundation Community Registry | July 11, 2022 | July 1, 2025 | |
| NCT05180162 | Recruiting | Phase 1 | Imaging of Pathologic Fibrosis Using 68Ga-FAP-2286 | December 9, 2021 | December 31, 2024 |
| NCT05299333 | Recruiting | N/A | Comparison of Pulmonary Telerehabilitation and Physical Activity Recommendations in Patients With Post Covid Fibrosis | September 4, 2022 | June 7, 2024 |
| NCT04170062 | Recruiting | N/A | Oxygen Savings With Administered Oxygen and High Flow Ambient Air At Rest | December 15, 2020 | December 31, 2024 |
| NCT05331300 | Recruiting | Phase 1/Phase 2 | A Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye Disease | June 6, 2022 | September 2025 |
| NCT00001532 | Recruiting | Role of Genetic Factors in the Development of Lung Disease | September 13, 1996 | ||
| NCT05365802 | Recruiting | Early Phase 1 | FAPI PET for Lung Fibrosis | November 16, 2021 | December 2026 |
| NCT04304898 | Recruiting | An International Patient-led Registry in Fibrotic Interstitial Lung Diseases Using eHealth Technology | May 1, 2020 | July 2026 | |
| NCT05740475 | Recruiting | Phase 1 | A Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of 9MW3811 in Healthy Subjects | March 20, 2023 | September 2023 |
| NCT04119115 | Terminated | Integrated Radiographic and Metabolomics Risk Assessment in Patients With Interstitial Lung Diseases | September 30, 2021 | October 20, 2022 | |
| NCT03267108 | Terminated | Phase 3 | A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis at Risk for Pulmonary Hypertension | December 14, 2020 | June 30, 2023 |
| NCT04253405 | Terminated | N/A | RENOVATE Fibrosis:HFNC Versus NIPPV in Acute Respiratory Failure in Patients With Pulmonary Fibrosis | December 10, 2020 | August 9, 2021 |
| NCT00076635 | Terminated | Phase 3 | An Open-Label Study of the Safety of Interferon Gamma-1b in Patients With IPF | November 2003 | April 2007 |
| NCT00467831 | Terminated | Phase 1/Phase 2 | Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome | April 2007 | November 2012 |
| NCT00690885 | Terminated | Phase 2 | Interferon-alpha Treatment of Chronic Cough in Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis | June 2008 | April 2012 |
| NCT00075998 | Terminated | Phase 3 | The INSPIRE Trial: A Study of Interferon Gamma-1b for Idiopathic Pulmonary Fibrosis (IPF) | December 2003 | May 2007 |
| NCT00981747 | Terminated | Phase 2/Phase 3 | Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis | September 2009 | December 2016 |
| NCT00052039 | Terminated | Phase 3 | A Randomized, Double-Blind, Three-Arm, Phase 3b Study Comparing the Safety and Efficacy of Interferon Gamma-1b With Azathioprine, and Azathioprine Alone in Patients With IPF Receiving Prednisone | April 2002 | June 2002 |
| NCT01203943 | Terminated | Phase 2 | A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF) | January 1, 2011 | August 24, 2012 |
| NCT01241942 | Terminated | N/A | Phase 2 Study of Ex-vivo Perfusion and Ventilation of Lungs to Assess Transplant Suitability | December 2010 | March 2013 |
| NCT00005295 | Terminated | Idiopathic Pulmonary Fibrosis: a Case-control Study | July 1989 | June 1995 | |
| NCT03103191 | Unknown status | Diagnostic Value of KL-6 in ILD | June 2016 | December 2023 | |
| NCT03056066 | Unknown status | Accuracy of Spircare Device as Compared to the Conventional Plethysmograph | July 31, 2017 | January 2019 | |
| NCT03103178 | Unknown status | Spanish Version of the KBILD Questionnaire | January 2017 | December 2019 | |
| NCT05121779 | Unknown status | Phase 1 | Head-to-head Comparison of Diagnosis Value of Pulmonary Fibrosis on 68Ga-FAPI-04 and 18F-FDG PET-CT | December 1, 2021 | December 1, 2023 |
| NCT00896155 | Unknown status | Phase 3 | Trial of Concurrent Versus Sequential Tamoxifen With Radiotherapy in Breast Cancer Patients | December 2008 | December 2013 |
| NCT04813575 | Unknown status | N/A | COVID-19 Pathophysiology of Long Term Implications | August 1, 2021 | June 1, 2022 |
| NCT04805086 | Unknown status | Phase 1/Phase 2 | The MONACO Cell Therapy Study: Monocytes as an Anti-fibrotic Treatment After COVID-19 | March 8, 2021 | March 5, 2023 |
| NCT00439543 | Unknown status | Phase 2/Phase 3 | Trial of Iloprost in Pulmonary Hypertension Secondary to Pulmonary Fibrosis | March 2007 | August 2007 |
| NCT02439528 | Unknown status | N/A | Genetics of the Combined Pulmonary Fibrosis and Emphysema Syndrome | March 2015 | December 2017 |
| NCT02496182 | Unknown status | Phase 2/Phase 3 | Pirfenidone in the Chronic Hypersensitivity Pneumonitis Treatment | July 2015 | January 2017 |
| NCT04537130 | Unknown status | Phase 1 | Vaccination of Ex-acute COVID-19 Patients With Fibrosing Lung Syndrome at Discharge | December 1, 2020 | June 2022 |
| NCT04517162 | Unknown status | Phase 1/Phase 2 | Intramuscular Effect of Polymerized Type I Collagen on the Cytokine Storm in COVID-19 Patients | August 19, 2020 | June 19, 2021 |
| NCT04416100 | Unknown status | Development of Interstitial Lung Disease (ILD) in Patients With Severe SARS-CoV-2 Infection (COVID-19) | April 29, 2020 | April 28, 2022 | |
| NCT04409275 | Unknown status | LUNG FIBROTIC CHANGES ASSOCIATED WITH SARS-CoV-2 INFECTION | May 21, 2020 | July 31, 2021 | |
| NCT05747508 | Unknown status | Phase 2 | A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis | December 29, 2017 | December 2023 |
| NCT01135199 | Withdrawn | Phase 2 | Pomalidomide for Cough in Patients With Idiopathic Pulmonary Fibrosis | April 2010 | June 2010 |
| NCT05676112 | Withdrawn | Safety of Nintedanib in Real World in China | December 29, 2023 | September 30, 2026 | |
| NCT02603068 | Withdrawn | Phase 2 | Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis | February 2016 | July 2018 |
- Disase is a (Disease Ontology)
- DOID:3082
- Cross Reference ID (Disease Ontology)
- MESH:D011658
- Cross Reference ID (Disease Ontology)
- NCI:C26869
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:155613001
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0034069
- Exact Synonym (Disease Ontology)
- Fibrosis of lung
- HPO alt_id (Human Phenotype Ontology)
- HP:0006523
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0002206
- MedGen concept unique identifier (MedGen Concept name)
- C0034069
- MedGen unique identifier (MedGen Concept name)
- 11028
- MeSH unique ID (MeSH (Medical Subject Headings))
- D011658